jeremiah@devisedesigns.com, Author at Corcept Therapeutics - Page 2 of 16

About jeremiah@devisedesigns.com

This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 156 entries already.

Entries by jeremiah@devisedesigns.com

Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

Pivonello et al. • 2025 • ESPE, ESE

May 10, 2025

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results

Badiu et al. • 2025 • ESPE, ESE

May 10, 2025

MONARCH: a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Alkhouri et al. • 2025 • MASH-TAG 2025 Congress

January 13, 2025

Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome)

Dr. Richard J. Auchus • 2024 • WCIRDC

December 13, 2024

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results

Araque et al. • 2024 • WCIRDC

December 12, 2024

Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

Araque et al. • 2024 • WCIRDC

December 12, 2024

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: Results from CATALYST

Fonseca et al. • 2024 • WCIRDC

December 12, 2024

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST

Handelsman et al. • 2024 • WCIRDC

December 12, 2024

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis

Badiu et al. • 2024 • AACE MENA 2024 Congress

November 25, 2024

Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)

Gilis-Januszewska et al. • 2024 • AACE MENA 2024 Congress

November 25, 2024

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Your Privacy Choices